VYNE recently announced positive results for its novel oral small molecule BD2-selective BET inhibitor in a single-ascending dose clinical trial.
Iain Stuart, PhD
Advertisement
Articles by Iain Stuart, PhD
Iain Stuart, PhD, discusses VYN202's status and potential in psoriasis and immuno-inflammatory diseases.
VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5
